The 10-second takeaway
For the quarter ended March 31 (Q3), Accuray missed slightly on revenues and exceeded expectations on earnings per share.
Compared to the prior-year quarter, revenue improved significantly and GAAP loss per share expanded.
Margins dropped across the board.
Accuray tallied revenue of $101.8 million. The six analysts polled by S&P Capital IQ hoped for sales of $103.9 million on the same basis. GAAP reported sales were 86% higher than the prior-year quarter's $54.7 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
EPS came in at -$0.13. The two earnings estimates compiled by S&P Capital IQ anticipated -$0.14 per share. GAAP EPS were -$0.21 for Q3 against -$0.02 per share for the prior-year quarter.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the quarter, gross margin was 35.5%, 1,440 basis points worse than the prior-year quarter. Operating margin was -14.1%, 1,750 basis points worse than the prior-year quarter. Net margin was -14.6%, 1,250 basis points worse than the prior-year quarter.
Next quarter's average estimate for revenue is $109.6 million. On the bottom line, the average EPS estimate is -$0.11.
Next year's average estimate for revenue is $414.8 million. The average EPS estimate is -$0.52.
The stock has a four-star rating (out of five) at Motley Fool CAPS, with 523 members out of 549 rating the stock outperform, and 26 members rating it underperform. Among 145 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 139 give Accuray a green thumbs-up, and six give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Accuray is outperform, with an average price target of $8.33.
The healthcare investing landscape is littered with also-rans and a few major winners. Is Accuray performing well enough for you? Read "Discover the Next Rule-Breaking Multibagger" to learn about a company David Gardner believes will deliver amazing returns during the next few years. Click here for instant access to this free report.
- Add Accuray to My Watchlist.
Seth Jayson had no position in any company mentioned here at the time of publication. You can view his stock holdings here. He is co-advisor of Motley Fool Hidden Gems, which provides new small-cap ideas every month, backed by a real-money portfolio. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.